MicroRNA-18a promotes cancer progression through SMG1 suppression and mTOR pathway activation in nasopharyngeal carcinoma

ShiJuan Mai1, RuoWen Xiao1, Lu Shi2, XiaoMin Zhou3, Te Yang4, MeiYin Zhang1, NuQing Weng1, XinGe Zhao1, RuiQi Wang1, Ji Liu1, Rui Sun5, HaiDe Qin4 and HuiYun Wang1

Abstract

miR-18a has been reported to be upregulated in nasopharyngeal carcinoma (NPC) tissues by microarray assays. However, the roles and the underlying mechanisms of miR-18a in NPC remain poorly understood. Here we demonstrated by real-time RT-PCR that miR-18a expression is upregulated in NPC tissues, and positively correlated with tumor size and TNM stage. Moreover, miR-18a expression could be upregulated by NF-κB activation or Epstein-Barr virus encoded latent membrane protein 1 expression. The ectopic expression of miR-18a promoted NPC cell proliferation, migration and invasion, while the repression of miR-18a had opposite effects. Candidate genes under regulation by miR-18a were screened out through a whole-genome microarray assay, further identified by a reporter assay and verified in clinical samples. SMG1, a member of the phosphoinositide 3-kinase-related kinases family and an mTOR antagonist, was identified as functional target of miR-18a. Our results confirmed that miR-18a exerts its oncogenic role through suppression of SMG1 and activation of mTOR pathway in NPC cells. Importantly, in vivo xenograft tumor growth in nude mice was effectively inhibited by intratumor injection of miR-18a antagomir. Our data support an oncogenic role of miR-18a through a novel miR-18a/SMG1/mTOR axis and suggest that the antitumor effects of antagomir-18a may make it suitable for NPC therapy.

Introduction

Nasopharyngeal carcinoma (NPC) is particularly common in Southern China and southeastern Asia, where the age-standardized incidence peaks at 30 per 100,000 person-years1,2. The multifactorial etiologies of NPC include genetic predisposition, Epstein-Barr virus (EBV) infection, and environmental factors3. Due to a highly invasive and metastatic character, 75-85% of NPC patients have metastatic nodes develop during the course of disease4. Although NPC is sensitive to radiotherapy and precise radiotherapy technologies and combined chemotherapy have improved the local control of NPC, the outcome of NPC in advanced stages is still poor, with the 5-year survival rate ranging from 41 to 63%5,6. Thus, there is an urgent need to explore the key factors leading to the progression of NPC and to develop additional targeted therapies for NPC.

MicroRNAs are known to play a pivotal role in tumorigenesis and cancer progression in humans. In particular, miR-17-92, a polycistron encoding six mature miRNAs, namely, miR-17, miR-18a, miR-19a, miR-20a, miR-19b, and miR-92a, is among the most potent oncogenic miRNAs7. Despite the overexpression of the miR-17-92 cluster in multiple cancer types, other studies suggest that the miR-17-92 cluster undergoes a loss of
heterozygosity and acts as a tumor suppressor in several
different cancers. Previous studies using miRNA micro-
array assays on NPC biopsies revealed that miR-18a,
derived from the miR-17–92 cluster, was significantly
upregulated in NPC tissues and might play important
roles in the development of NPC. However, the role of
miR-18a in NPC and the underlying molecular mechan-
ism by which miR-18a promotes NPC development
remain incompletely understood; only one recent study
has reported that miR-18a could promote NPC cell pro-
liferation by targeting the miRNA-processing enzyme
DICER1.

Here, we demonstrate that miR-18a (also named miR-
18a-5p) expression is upregulated in NPC tissues and is
positively correlated with tumor size and TNM stage of
NPC by using a quantitative real-time RT-PCR (qRT-
PCR) assay on NPC biopsies. The ectopic expression of
miR-18a in NPC cells promotes cell survival, epithelial
mesenchymal transition (EMT) and invasion. Further-
more, we provide evidence that miR-18a promotes the
activation of the mTOR pathway by directly targeting
SMG1 gene expression. In addition, we have shown that
miR-18a expression can be induced by EBV encoded
latent membrane protein 1 (LMP1) or NF-κB activation.
Thus, the results reveal a novel mechanism by which miR-
18a-mediated signaling facilitates the progression of
NPC cells.

Materials and methods
Cell lines, antibodies, and reagents
The human NPC cell lines CNE1, CNE2, S-18, S-26, S-
8F, 6-10B, SUNE2 and C666-1 cells were preserved in our
cancer center and routinely maintained in RPMI-1640
containing 100 units/ml penicillin, 100 μg/ml streptomycin,
and 10% FBS (Invitrogen, CA, USA) at 37 °C in a 5%
CO2 humidified atmosphere. HK1 cells were cultured in
RPMI1640 supplemented with 5% FBS. NP69, an
immortalized human nasopharyngeal epithelial cell line,
was cultured in defined keratinocyte serum-free medium
supplemented with epidermal growth factor (Invitrogen,
CA, USA). C666-1 is the only in vitro native EBV-infected
NPC cell line. Other NPC cell lines have lost EBV in long-
term cultures thus are EBV-negative. All of the normal
nasopharyngeal epithelial cell lines and NPC cell lines
were generously provided by Professor MuSheng Zeng
(Sun Yat-sen University Cancer Center) with authenti-
cated using short tandem repeat profiling, tested for
Mycoplasma contamination.

Mouse monoclonal antibodies against human E-cad-
herin, N-cadherin and Vimentin were purchased from
BD Biosciences (BD Transduction Laboratories, Lex-
ington, UK). Rabbit polyclonal antibody against Snail
was purchased from Proteintech (Wuhan, China). Rab-
bit monoclonal antibodies against human phosphop70S6K (Thr389), p70S6K, phospho-4E-BP1, and 4E-BP1 were obtained from Cell Signaling Tech-
nology (Danvers, MA, USA). Mouse monoclonal anti-
bodies against EBV LMP1 and SMG1 were purchased
from Abcam (Cambridge, UK).

To induce or inhibit NF-κB activity, NPC cells were
treated with 10 ng/ml TNF-α (Sigma, St Louis, MO, USA)
or 2.5 μM BAY 11-7082 (Selleck Chemicals, Houston, TX,
USA), respectively, before luciferase analysis or evaluation
of miR-18a expression by qRT-PCR. For rapamycin
treatment, cells were pretreated with 20 ng/ml of rapa-
mycin (Selleck Chemicals, Houston, TX, USA) for 30 min
before the following experiments.

Clinical samples
Twenty-one cases of fresh NPC tissues and 14 non-
cancerous nasopharyngitis (NP) tissues were used for
qRT-PCR detection of miR-18a. Twelve paired fresh
NPC tissues and adjacent noncancerous nasopha-
ryngeal mucosal tissues were used for qRT-PCR detec-
tion of SMG1 and miR-18a. All fresh samples were
collected at the time of diagnosis and preserved in
liquid nitrogen until further use. Formalin-fixed para-
fin-embedded tissues of 67 primary NPC tissues were
obtained from the archives of the Department of
Pathology in the Cancer Center, Sun Yat-sen Uni-
versity, between January 2007 and December 2008. All
patients were histologically and clinically diagnosed as
NPC, assessed according to the TNM staging of Inter-
national Union against Cancer. None of the patients
received radiotherapy or chemoradiotherapy before
biopsy sampling. This study was approved by the
Research Ethics Committee of Sun Yat-sen University
Cancer Center, and written informed consent was
obtained from each participant.

Vectors and transfection
Lentivirus overexpressing miR-18a was purchased from
GenePharma (Shanghai, China). NPC cells were infected
with recombinant lentivirus transducing units plus 8 mg/
ml Polynbrene (Sigma, St Louis, Missouri, USA). Stable cell
lines were selected using 4 μg/mL puromycin. Transient
transfection was performed using Lipofectamine 2000
reagent (Invitrogen, CA, USA) in OPTI-MEM media.
miR-18a mimic, mir-18a inhibitor, siRNA against LMP1
or SMG1 and their negative controls were obtained from
RiboBio (Guangzhou, China). pcDNA3.1(+)-LMP1 plas-
mid was kindly provided by Professor BiJun Huang (Sun
Yat-sen University Cancer Center).

RNA extraction and qRT-PCR
Total RNA was extracted from cell lines and fresh tis-
sues with TRIzol reagent (Invitrogen, CA, USA) or
paraffin-embedded tissues with phenol chloroform
according to the manufacturer’s instructions. cDNA was synthesized with the PrimeScript RT reagent Kit (Promega, Madison, WI, USA). Quantitative real-time PCR analysis was carried out using TaqMan Reverse Transcription Kits and the TaqMan Assays (Life Technologies, Darmstadt, Germany). U6 and GAPDH were used as the internal controls for the quantification of miR-18a and SMG1, respectively. Quantitative RT-PCR was carried out on the Roche LightCycler® 96 real-time PCR platform, and gene expression was quantified using the $2^{-\Delta\Delta CT}$ method.

**Western blot**

Total protein was extracted from cultured cells using RIPA buffer containing PMSF and quantified using a BCA protein assay kit (Beyotime, Haimen, China). Protein lysates were subjected to SDS-PAGE and transferred onto polyvinylidenedifluoride membranes (Millipore, Billerica, MA), followed by incubation first with a primary antibody and then with a secondary antibody. The signals were detected with the KeyGEN Enhanced ECL detection kit according to the manufacturer’s instructions (KeyGEN, NanJing, China).

**Microarray assay**

miR-18a knockdown 5-8F cells and miR-18a overexpressing 6-10B cells and their corresponding control cells were selected for microarray analysis. Total RNA was isolated from cell lines using TRizol reagent (InVitrogen, CA, USA) according to the manufacturer’s instructions. RNA quantity and quality were measured by NanoDrop ND-1000. RNA integrity was assessed by standard denaturing agarose gel electrophoresis. HumanGene Expression 4×44k v2 Microarray Kit (Agilent Technologies) were used to monitor changes in gene expression. The microarray analysis was performed by Kangchen Bio-tech Inc (Shanghai, China). Sample labeling and array hybridization were performed according to the Agilent One-Color Microarray-Based Gene Expression Analysis protocol (Agilent Technology). Agilent Feature Extraction software (version 11.0.1.1) was used to analyze acquired array images. Quantile normalization and subsequent data processing were performed with using the GeneSpring GX v12.1 software package (Agilent Technologies). Our microarray studies utilize no replication due to practical considerations of cost. Therefore, the threshold of two-fold change was defined to identify differentially expressed genes and qRT-PCR was performed to validate and quantify the differentially expressed genes related with PI3K/AKT/mTOR or EMT network to verify the reliability of the microarray results. The qRT-PCR results were generally consistent with the microarray data.

**Immunohistochemistry (IHC)**

IHC was performed using a standard streptavidin-biotin-peroxidase complex method. In brief, slides with paraffin-embedded sections were deparaffinized and rehydrated. Endogenous peroxidase activity was blocked with 0.3% hydrogen peroxide for 15 min. For antigen retrieval, the slides were microwave-treated and boiled in a 10 mM citrate buffer (pH 6.0) for 10 min. The slides were incubated overnight at 4°C with primary antibody. The staining results were evaluated independently by two pathologists.

**Cell viability assay**

Cell viability was detected by the CCK8 Cell Counting Kit (JingXin Biological Technology, Guangzhou, China). Cells were plated and cultured in 96-well plates at a density of $1.0 \times 10^3$ cells/well. The detection was performed at the same time every day. The OD value was measured at 450 nm by a microplate reader (SpectraMax® M5 Multimode Microplate Reader; Molecular Devices, LLC, Sunnyvale, CA, USA). All experiments were performed in triplicate.

**Colony formation assay**

Cells were placed in six-well plates (300 cells/well) and cultured for 2 weeks. Colonies were fixed with methanol and stained with 0.1% crystal violet in 20% methanol for 15 min. Colonies larger than 0.1 mm in diameter were scored. The experiment was performed in triplicate for each cell line.

**Wound healing and invasion assays**

Cell migration was measured by a scratch wound-healing assay. The culture medium was replaced with serum-free DMEM after the generation of a scratch wound, and wound closure was photographed 24 h later. The scratch closures were later analyzed and are represented as percent closure in the figures. For invasion assays, $5 \times 10^4$ cells were plated in a Matrigel-coated Transwell chamber (BD Biosciences, Lexington, UK) with an 8 μm pore size. The noninvading cells were removed 16 h later, and the invaded cells on the bottom of the chamber were fixed with 100% methanol and stained with crystal violet. The experiments were performed in triplicate.

**Animal study**

Six-week-old male athymic BALB/c nude mice were injected subcutaneously with $4 \times 10^5$ control or miR-18a-overexpressing HK1 cells ($n=5$ per group). Randomization was conducted. Tumor sizes were measured using calipers every 4 days using an unblinded manner, and tumor volumes were calculated ($V=0.5 \times L \times W^2$). Mice were sacrificed 40 days after inoculation and tumors were...
fixed in formalin, embedded in paraffin and used for hematoxylin-eosin (H&E) staining and IHC assays. For antagonir treatment, 4-week-old male athymic BALB/c nude mice were injected subcutaneously with $6 \times 10^6$ 5-8F cells. Antagonirs were synthesized by RiboBio Co. (Guangzhou, China). After 15 days, when the tumors became palpable, the tumor-bearing mice were assigned to two groups (five mice per group) randomly. 20 nmol antagonir-18a for test group or negative control for control group was injected intratumorally in a multisite injection manner every 3 days for 2 weeks. Tumor volumes and weights were calculated as described above. All animal studies were approved by the laboratory animal ethics committee of Sun Yat-sen University Cancer Center.

Luciferase reporter assay

miR-18a belongs to the miR-17–92 cluster. The potential NF-kB binding sites were predicted in the 2000 bp upstream region of the transcription start site (chr13: 72,977,942–72,979,921) of miR-17–92 by the TFSEARCH (http://www.cbrc.jp/research/db/TFSEARCH.html) and MOTIF (http://motif.genome.jp/). Next, three miR-17–92 promoters (–1747 to –1583, –1583 to –1328, and –1328 to –790) that spanning the putative NF-kB binding sites at –1698 (TGGAATTTCC), –1442 (TGGAATTTCC) and –827 (CGGAATTTCC) respectively were constructed by PCR using primers reported by Zhou et al.13, and transfected into 5-8F cells. The transfected cells were treated with TNF-α or BAY 11-7082 respectively for 24 h followed by measurement of luciferase activity, which was presented as the ratio of the activity of the test construct with the control pGL4-basic vector. All constructs were confirmed by sequencing.

Oligonucleotides containing the wild-type (Wt) or mutant (Mut) putative miR-18a binding sites in the 3′-untranslated regions (3′-UTR) of SMG1 mRNA were separately ligated into the pMIR-REPORT vector (Ambion, Carlsbad, CA). 6-10B cells were transfected with luciferase constructs in the presence of a miR-18a mimic or negative control.

For reporter assay, a total of $4 \times 10^4$ cells per well were seeded in 24-well plates in triplicate. Twenty-four hours later, 100 ng of firefly luciferase construct was cotransfected with 10 ng of pRL-TK renilla plasmid into cells using Lipofectamine 2000 reagent. Media were replaced at 6 h, and the luciferase and renilla signals were measured 48 h after transfection using the Dual Luciferase Reporter Assay Kit (Promega, Madison, WI, USA) according to the manufacturer’s protocol. The experiments were performed independently in triplicate.

Statistical analysis

Sample size was chosen based on the need for statistical power. All experiments were repeated three times or more and data are presented as mean ± SD and Student’s t-test (unpaired, two-tailed) was used to evaluate significant differences between groups of experimental data where appropriate. The variance between the groups that are being statistically compared is similar. The Chi-square test was used for correlation analysis between clinicopathological features of patients with NPC and miR-18a expression profiles. The linear correlations between miR-18a and SMG1 mRNA expression in NPC tissues were evaluated with Pearson correlation coefficient analysis. In addition, repeated measure analysis of variance was used to compare the difference of tumor volume between groups of mice treated with antagonirs during the subsequent measurements. The SPSS version 17.0 statistical software package was used for statistical analyses. $P < 0.05$ was regarded as statistically significant ($^* P < 0.05; ^{**} P < 0.01; ^{***} P < 0.001$).

Results

miR-18a is overexpressed in NPC and is associated with tumor stage

The expression level of miR-18a was evaluated in 21 snap-frozen NPC tissues and 14 noncancerous nasopharyngitis (NP) tissues by qRT-PCR. The results showed that the miR-18a expression level was significantly upregulated in tumor compared with non-tumor tissues ($P = 0.0381$, Fig. 1a). The miR-18a expression level was further determined in the immortalized non-neoplastic cell line NP69 and a panel of NPC cell lines (CNE1, CNE2, 6-10B, 5-8F, S-18, S-26, HK1, C666-1, and SUNE2) (Fig. 1b). It was shown that the basal expression level of miR-18a was lowest in NP69 cells. 5-8F (high tumorigenic and metastatic potential) and 6-10B (low tumorigenic and metastatic potential) are paired cell lines derived from the NPC cell line SUNE-1, and S18 (high tumorigenic and metastatic potential) and S26 (low tumorigenic and metastatic potential) were derived from CNE2 cells. The miR-18a expression level was significantly higher in 5-8F and S-18 cells than in their paired subclones 6-10B and S-26 cells.

To determine the correlation of miR-18a level with the clinicopathological features in NPC patients, qRT-PCR was performed on an additional 67 formalin-fixed, paraffin-embedded primary NPC tissues. The expression levels of miR-18a were classified into high ($n = 34$) and low level ($n = 33$) groups according to the median value of miR-18a expression. The clinicopathological parameters of the 67 NPC patients were summarized in Table 1. As shown, high miR-18a expression was positively associated with tumor size ($P = 0.0021$) and clinical stage ($P = 0.0049$). No significant associations were found between miR-18a expression and the other clinicopathological features. These results suggest that miR-18a plays a promoting role in NPC progression.
Fig. 1 (See legend on next page.)
miR-18a promotes NPC cell growth, migration, and invasion

Stably miR-18a-expressing HK1 and 6-10B cells were constructed using lentiviral transfection and endogenous miR-18a was knocked down in 5-8F cells with an anti-sense oligonucleotide inhibitor. miR-18a expression was validated by qRT–PCR (Fig. 1c). The CCK8 assay showed that miR-18a overexpression significantly increased the growth rate in both NPC cell lines compared with that in the control cells, whereas miR-18a inhibitor retarded cell growth in 5-8F cells (Fig. 1c).

In wound-healing assays, the motility of HK1-miR-18a and 6-10B-miR-18a was remarkably increased compared with that of the control cells at 24 h post-wounding (Fig. 1d). Next, cell invasion ability was evaluated through a Matrigel-coated Transwell insert. Stable overexpression of miR-18a increased the invasion ability of HK1 and 6-10B cells (Fig. 1e). Conversely, transient transfection of 5-8F cells with a miR-18a inhibitor substantially decreased cell migration and invasion ability (Fig. 1d, e).

To further investigate the molecular mechanism mediating the aggressive effect of miR-18a, we examined the potential regulation of miR-18a on EMT. Western blot analysis revealed that the mesenchymal markers N-cadherin, Vimentin and core EMT transcription factor Snail were significantly upregulated, and the expression of the epithelial marker E-cadherin was decreased, in the miR-18a-expressing HK1 and 6-10B cells. The opposite results were obtained in the 5-8F cells transfected with a miR-18a inhibitor (Fig. 1f).

Taken together, these data showed that miR-18a enhanced malignant phenotypes in NPC cells in vitro.

Identification of the miR-18a target genes

To search for molecular processes underlying miR-18a-mediated oncogenesis in NPC cells, whole-genome mRNA microarray analysis was performed using the HumanGene Expression 4 × 44k v2 Microarray Kit (Agilent Technologies) in 6-10B cells with stable miR-18a overexpression and in 5-8F cells with transient silencing of miR-18a by siRNA. We identified 2622 differentially expressed genes (fold change > 2), namely, 1319 down- and 1303 upregulated genes, in miR-18a-overexpressing cell and 4159 differentially expressed genes (fold change > 2), namely, 1835 down- and 2324 upregulated genes, in miR-18a knockdown cells. Differentially expressed genes (n = 390) that simultaneously downregulated in the miR-18a-overexpressing cells and upregulated in the miR-18a-suppressed cells were subjected to Gene Set Enrichment Analysis (Fig. 2a). We found that the top-scoring canonical pathways include PI3K/AKT/mTOR and EMT related signaling pathway. Negative regulator of the PI3K/AKT/mTOR or EMT network including SMG1, PPP2R1B, DLC1 and ATXN1 were reduced by miR-18a, PI3K/AKT/mTOR pathway components including AKT2 and PIK3R3 or upstream regulator EGFR, FGF9 and IL7 were induced by miR-18a (Fig. 2b). To verify the reliability of the microarray results, qRT-PCR was performed to validate and quantify the differentially expressed genes related with PI3K/AKT/mTOR or EMT network, including five that were upregulated (FGF9, IL7, PIK3R3, AKT2, and EGFR) and four that were downregulated (SMG1, PPP2R1B, DLC1, and ATXN1) by miR-18a. Primers used for qRT-PCR were listed in the Supplementary Table 1. The qRT-PCR results of these genes were generally consistent with the microarray data (Supplementary Fig. 1). To identify putative targets of miR-18a in NPC cells, we integrated the differentially expressed genes from our microarray approaches (n = 390) and predicted miR-18a targets by TargetScan (release 7.1) (n = 317). Nine genes including UHMK1, CSorf30, SMG1, LNPEP, NCOA2, ATXN1, SLC6A6, NEDD9, and ANKRD50 were selected as the candidate targets of miR-18a (Fig. 2c). SMG1 (nonsense-mediated mRNA decay associated PI3K related kinase) has been reported to be a member of the phosphoinositide 3-kinase-related kinases family and act as an mTOR antagonist. Therefore, we particularly focused on SMG1 in the following experiments. The expression profile of SMG1 in microarray data was summarized in Supplementary Table 2.

SMG1 is directly targeted by miR-18a and downregulated in NPC

Putative miR-18a target sites in the 3′UTR of SMG1 mRNA were predicted by the TargetScan (Fig. 2d, left). To validate SMG1 as a direct target of miR-18a, reporter plasmids containing the wild-type or target site-mutated 3′UTR fragments of SMG1 were constructed. As expected, the luciferase activities of the reporter containing the wild-type 3′UTR in 6-10B cells were reduced significantly after transfection with miR-18a mimics. No obvious change in luciferase expression was found in cells.
transfected with reporters containing mutations in the miR-18a binding sites in the SMG1 3′UTR (Fig. 2d, right). In agreement with the bioinformatic predictions and reporter assay, the protein level of SMG1 was downregulated in HK1 and 6-10B cells in response to the miR-18a mimic and upregulated in 5-8F cells transfected with the miR-18a inhibitor (Fig. 2e). These results suggest that SMG1 is a direct functional target of miR-18a in NPC.

To explore the expression level of SMG1 in NPC patients, we compared SMG1 mRNA expression levels in 12 paired fresh NPC tissues and adjacent noncancerous nasopharyngeal mucosal tissues by using qRT-PCR. The results showed that SMG1 was significantly downregulated in tumor tissues compared with non-tumor tissues (\(P < 0.001\)) (Fig. 2f). Moreover, an inverse correlation between miR-18a and SMG1 mRNA expression was determined in 12 NPC tissue samples by using qRT-PCR analysis (\(P = 0.0039\), Fig. 2g).

miR-18a exerts oncogenic effects through the suppression of SMG1

As miR-18a has been shown to promote NPC cells migration and invasion, we hypothesized that SMG1, as a predicted target gene of miR-18a, might play an opposite role in NPC. To test this hypothesis, endogenous SMG1 in HK1, 6-10B, and 5-8F cells was silenced by SMG1-specific siRNA oligos. The Matrigel-coated Transwell assay showed that the average number of invading HK1, 6-10B, and 5-8F cells transfected with siRNAs against SMG1 was significantly higher than that of cells treated with control siRNA (Fig. 3a).

Next, we set out to corroborate whether SMG1 suppression mediates the role of miR-18a in cancer cells. For the rescue experiment, it is better to cotransfect miR-18a mimics and SMG1-expressing plasmid into NPC cells. Unfortunately, we failed to construct SMG1 overexpressing plasmid since the coding sequence of SMG1 gene (NM_015092.4) reach 10,986 bp in length. Alternatively, SMG1-targeting siRNA and miR-18a inhibitors were cotransfected into HK1, 6-10B and 5-8F cells, respectively. Whereas miR-18a suppression inhibited the potential for colony formation and invasion, simultaneous treatment with SMG1 siRNA recovered the oncogenic phenotypes (Fig. 3b, c). Furthermore, western blot analysis demonstrated that EMT induction was restored by the introduction of SMG1 siRNAs into HK1, 5-8F and 6-10B cells transfected with the miR-18a inhibitor (Fig. 3d). These results suggest that SMG1 induction mediates the effects of miR-18a inhibition in cancer cell migration and invasion.

SMG1-dependent mTOR signaling activation is essential for miR-18a-stimulated promotion of cellular motility in NPC cells

To examine the role of miR-18a expression in mediating the levels of activated mTOR, we detected the phosphorylated forms of downstream effectors in the AKT/

| Characteristics                  | Number of cases | miR-18a expression | \(P\) value |
|----------------------------------|-----------------|--------------------|-------------|
|                                 |                 | Low, \(n, \%\)     | High, \(n, \%\) |
| Age                              |                 |                    |             |
| \(\leq 45\) years                | 23              | 15 (44)            | 8 (24)      | 0.0867 |
| >45 years                        | 44              | 19 (56)            | 25 (76)     |         |
| Gender                           |                 |                    |             |
| Male                             | 48              | 26 (76)            | 22 (67)     | 0.3734 |
| Female                           | 19              | 8 (24)             | 11 (33)     |         |
| EBV DNA copy                     |                 |                    |             |
| \(\leq 4000\)                    | 30              | 17 (50)            | 13 (39)     | 0.3828 |
| >4000                            | 37              | 17 (50)            | 20 (61)     |         |
| VCA-IgA                           |                 |                    |             |
| \(<1:10\)                        | 22              | 14 (41)            | 8 (24)      | 0.1400 |
| \(\geq 1:10\)                    | 45              | 20 (59)            | 25 (76)     |         |
| CVA-IgA                           |                 |                    |             |
| \(<1:80\)                        | 18              | 12 (35)            | 6 (18)      | 0.1141 |
| \(\geq 1:80\)                    | 49              | 22 (65)            | 27 (82)     |         |
| Histology, WHO type              |                 |                    |             |
| III                              | 66              | 34 (100)           | 32 (97)     |         |
| II                               | 0               | 0                  |             |         |
| I                                | 1               | 0                  | 1 (3)       |         |
| T stage                          |                 |                    |             |
| T1–T2                            | 31              | 22 (65)            | 9 (27)      | 0.0021 |
| T3–T4                            | 36              | 12 (35)            | 24 (73)     |         |
| N stage                          |                 |                    |             |
| N0–N1                            | 34              | 20 (59)            | 14 (42)     | 0.1795 |
| N2–N3                            | 33              | 14 (41)            | 19 (58)     |         |
| M stage                          |                 |                    |             |
| M0                               | 40              | 24 (71)            | 16 (48)     | 0.0652 |
| M1                               | 27              | 10 (29)            | 17 (52)     |         |
| TNM stage                        |                 |                    |             |
| I–II                             | 21              | 16 (47)            | 5 (15)      | 0.0049 |
| III–IV                           | 46              | 18 (53)            | 28 (85)     |         |

VCA-IgA, viral capsid antigen immunoglobulin A; EA-IgA, early antigen immunoglobulin A

Significant \(P\) values were shown in bold
Fig. 2 (See legend on next page.)
mTOR signaling pathway by western blotting. Overexpression of miR-18a in HK1 and 6-10B cells upregulated the levels of p70S6K and 4EBP1 but had no effect on the total levels of the proteins. In contrast, knockdown of miR-18a in 5-8F cells dramatically reduced phospho-S6K and p-4EBP1 levels (Fig. 4a). To confirm that mTOR pathway activation was critical in miR-18a-promoted invasion and metastasis, we examined the effect of the mTOR inhibitor rapamycin on the enhanced invasion stimulated by miR-18a. The western blot assay showed that the EMT phenotype induced by miR-18a was suppressed by rapamycin treatment (Fig. 4b). In addition, the increased invasion of miR-18a overexpressing HK1, 6-10B, and 5-8F cells was suppressed by rapamycin treatment (20 ng/ml) (Fig. 4c). These findings confirmed that miR-18a promotes cellular motility and EMT in NPC cells through mTOR signaling.

To confirm that the activation of the mTOR pathway by miR-18a is indeed SMG1-dependent in NPC cells, we first examined the expression of the mTOR signaling-related molecules in 6-10B cells after RNAi-mediated silencing of SMG1. As expected, we observed that phosphorylated mTOR, p70S6K and 4EBP1 were significantly increased by SMG1 inhibition in NPC cells (Fig. 4d). Moreover, western blot analysis demonstrated the restoration of phosphorylated p70S6K and 4EBP1 by the inhibition of SMG1 in HK1 and 5-8F cells transfected with the miR-18a inhibitor (Fig. 4e). All of these findings confirmed that the oncogenic role of miR-18a in NPC cells depends on SMG1/mTOR signaling.

Suppression of NPC cell growth by antagonomir-18a in mouse xenografts

To further confirm the growth-stimulating effect of miR-18a, we conducted an in vivo tumor formation experiment by subcutaneously injecting HK1-miR-18a or the control cells into nude mice. At 40 days after implantation, the mice injected with HK1-miR-18a cells had significantly heavier tumor burdens than their controls (Fig. 5a).

The above results suggest that miR-18a might be a potential therapeutic target in NPC. To address this hypothesis, subcutaneous tumors formed by 5-8F cells in nude mice were treated with antagonomir-18a injections once every 3 days for 2 weeks. The treatments, which started at 15 days post-tumor cell implantation, began to inhibit tumor growth after the second injection (Fig. 5b), with no obvious difference in body weight between the two groups of mice (data not shown). IHC staining on tumor sections showed a marked increase in SMG1 and E-cadherin protein levels and a decrease in Snail, p-4EBP1, Vimentin and Ki-67 protein levels in the antagonomir-18a treated group (Fig. 5c). Interestingly, weaker staining of SMG1 was observed in the edges of the tumor masses than in the centers, in contrast with the staining of Ki-67, Snail and Vimentin, which was stronger in the tumor edges than in the centers (Supplementary Fig. 2).

miR-18a can be induced by NF-κB activation and LMP1 expression in NPC cells

Since multiple putative NF-κB activation sites were predicted in the promoter region of miR-18a, we suggest that NF-κB activation might regulate miR-18a expression. To identify the effect of NF-κB activity on miR-18a expression, BAY 11-7082, an NF-κB inhibitor, was used to inhibit IKKα/β activation, which leads to the translocation of p65 into the nucleus. The miR-18a expression levels were examined in NPC cells following pretreatment with BAY 11-7082 by qRT-PCR. As shown in Fig. 6a, decreased expression of miR-18a was observed in the BAY 11-7082-pretreated 5-8F and 6-10B cells. In contrast, the activation of NF-κB signaling by TNF-α treatment increased miR-18a levels in NPC cells (Fig. 6b). Moreover, dual-luciferase reporter assay demonstrated that TNF-α induced NF-κB activation increased luciferase activity in NPC cells transfected with the luciferase constructs that encompass the putative NF-κB binding site at −827 or −1442 compared with the PGL4-basic construct. Luciferase activity of the construct containing the binding site -1698 was also elevated but did not reach statistical significance (P = 0.0793) (Supplementary Fig. 3). On the contrary, NF-κB inhibitor BAY 11-7082 treatment repressed luciferase activity of the constructs spanning the putative NF-κB binding site at −827, −1442 or −1698. Our results suggest that NF-κB activation might induce miR-18a expression by binding to the promoter regions of miR-18a.
Fig. 3 miR-18a exerts oncogenic effects through the SMG1 suppression. a Invasion assay with HK1, 6-10B and 5-8F cells transfected with siRNA against SMG1 or with a negative control. Suppression of SMG1 expression by siRNA restored the reduced colony formation (b), invasion ability (c), and EMT phenotypes (d) in miR-18a inhibitor-treated HK1, 6-10B and 5-8F cells. Data are presented as the mean ± SD. All assays were done in triplicate, and the values represent the mean of three independent experiments. **P < 0.01; ***P < 0.001
It was known that LMP1 engages signaling proteins in the tumor necrosis factor receptor family and leads to the activation of NF-κB. Therefore, we set out to examine whether LMP1 affects the expression of miR-18a. The EBV-negative NPC cell lines 5-8F and 6-10B were transiently transfected with the pcDNA3.1-LMP1 plasmid (a kind gift from Dr. Bi-Jun Huang from Cancer Center, SYSU) or an empty plasmid, and C666-1, an EBV-positive NPC cell line, was transfected with LMP1-specific siRNA. Quantitative RT-PCR analysis demonstrated elevated expression of miR-18a in LMP1-transfected cells compared to control cells, whereas suppression of miR-18a was detected in siLMP1-transduced C666-1 cells compared to control cells (Fig. 6c); these results suggest that...
Fig. 5 (See legend on next page.)
LMP1 might induce the expression of miR-18a in NPC cells.

To further confirm the effects of LMP1 expression on SMG1 expression and mTOR activation in NPC cells, LMP1 was expressed in 5-8F and 6-10B cells by transfection of pcDNA3.1-LMP1 plasmid and inhibited in C666-1 cells by siRNA-LMP1 transfection, respectively. Western blot assays showed that phosphorylated p70S6K and 4EVP1 were increased after LMP1 expression and decreased after LMP1 inhibition (Fig. 6d).

Discussion

The role of miR-18a in tumor progression remains controversial. miR-18a has been proposed to promote cancer progression in colon cancer and NPC12,15 but to inhibit tumor growth in glioblastoma, colorectal cancer, and basal-like breast cancer16–18. Although miRNA microarray assays have demonstrated the upregulation of miR-18a in NPC samples, the exact function of miR-18a in NPC cells has not yet been fully defined. A recent study reported that NPC cells transfected with miR-18a exhibited significantly decreased expression of DICER1 mRNA and protein but significantly increased proliferative and invasive properties compared to control cells, and the authors suggested that miR-18a expression might promote the proliferation and metastasis of NPC cells by regulating DICER112. The downregulation of DICER1 mRNA by 2.56-fold in miR-18a-overexpressing 6-10B cells compared with control cells was also confirmed by the microarray assay in the present study (data not shown). However, which oncogenic pathways were regulated by miR-18a and mediated the oncogenic functions of miR-18a in NPC was still unclear.

Here, we demonstrate that enforced expression of miR-18a promoted NPC cell proliferation, invasion and EMT, whereas miR-18a knockdown produced the opposite effects. Moreover, qRT-PCR analysis demonstrated that miR-18a was significantly overexpressed in NPC patients and was associated with tumor size and TNM stage, a finding that is in line with those of previous microarray studies showing that miR-18a is overexpressed in NPC tissues and correlates with poor prognosis9–11.

To identify the genes correlated with miR-18a in NPC, we analyzed genes differentially expressed after miR-18a overexpression or knockdown by whole-genome microarray analysis. KEGG pathway analysis revealed top-scoring enrichment of the PI3K/AKT/mTOR pathway. One of the most important findings here is that SMG1, which is a recently characterized member of the phosphoinositide 3-kinase-related kinases family and has been previously identified to be a critical component of nonsense-mediated mRNA decay (NMD), was verified as a functional target of miR-18a. Despite the involvement of SMG1 in NMD, the role of SMG1 in carcinogenesis has been explored in recent years. Haploinsufficiency for SMG1 predisposes mice to the formation of a range of tumors, suggesting that SMG1 might be a key tumor suppressor19. Additionally, decreased SMG1 expression has been shown in acute myeloid leukemia (AML), colorectal cancer, hepatocellular carcinoma and HPV-positive head and neck squamous cell carcinoma cells20–24. However, to date, the expression and function of SMG1 in NPC have not been reported. Here, we demonstrated for the first time that SMG1 expression is inhibited by miR-18a and is significantly reduced in NPC tissues. Importantly, we identified SMG1 as a potential negative regulator of EMT and cell invasion in NPC, suggesting a tumor-suppressive role of SMG1 in NPC. Moreover, the immunohistochemical analyses in our mice xenograft tumor models showed the intense Ki-67, Snail and Vimentin staining at the edge of tumors, a region where tumor cells were considered to have higher growth and invasive potential. By contrast, a decreased number of SMG1-expressing cells was observed at the edges compared with the central portions of the tumors, supporting the suppressive role for SMG1 in advancing tumor growth in NPC.

Consistent with our microarray data, immunoblotting analysis confirmed that the overexpression of miR-18a increased the phosphorylation of the mTOR downstream effectors p70S6K and 4EBP1, while the knockdown of
endogenous miR-18a exerted opposite effects. Since mTOR pathway was commonly over-activated and promoted cell invasion and metastasis in NPC, rapamycin treatment was supposed to reduce EMT and invasion ability in both NC and miR-18a-expressing groups (as shown in Fig. 4b, c). Upon rapamycin treatment, the induced invasion ability of 5-8F and 6-10B cells by miR-18a was almost completely abrogated (Fig. 4c), indicating that the mTOR pathway mediates the oncogenic role of miR-18a in NPC. However, miR-18a induced invasion in HK1 cells was only partially reduced by rapamycin treatment comparing with NC (Fig. 4c), which indicates that miR-18a might enhance HK1 cell invasion through other pathway besides mTOR. Actually, it has been reported previously that miR-18a regulate EMT and metastasis by targeting SMAD2, DICER1, CDC42 or HIF1A. Thus, miR-18a might induce NPC cell invasion through multiple targets.

Both SMG1 and mTOR belong to the phosphoinositide 3-kinase-related kinases family, and an antagonistic
interaction between SMG1 and mTOR signaling was suggested by recent studies. Cristina et al. first reported that SMG1 and mTORC1 act antagonistically in planarian flatworms. Later, Du et al. verified a negative correlation between mTOR and SMG1 expression levels in AML patients. In the present study, we confirmed that the phosphorylation of mTOR signaling pathway molecules was upregulated by SMG1 knockdown. Moreover, the suppression of the mTOR pathway by miR-18a inhibitor was abolished upon knockdown of SMG1, suggesting that miR-18a regulated the mTOR signaling pathway in an SMG1-dependent manner. The above findings confirmed that miR-18a exerts its oncogenic roles through SMG1 inhibition and mTOR activation in NPC.

In this study, NF-κB activation was suggested to induce miR-18a. The expression of miR-18a was increased after TNF-α treatment and decreased in NF-κB inhibitor BAY 11-7082 treated NPC cells. Indeed, direct binding of the NF-κB p65 subunit to the promoter element of the miR-17-92 gene has been confirmed by chromatin immunoprecipitation and luciferase reporter assays in a previous study. And in the present study, we verified by a dual-luciferase reporter gene system that NF-κB activation could induce miR-18a expression by binding to multiple putative binding sites in its promoter regions (Supplementary Fig. 3). NF-κB overexpression can be observed in almost all NPC tumors and plays an important role in NPC tumorigenesis. As a prosurvival transcription factor, NF-κB has been reported to regulate sets of miRNAs in lung cancer, esophageal cancer and gastric cancer. Interestingly, miR-18a has been reported to target the TNF-α-induced protein 3 (TNFAIP-3), an NF-κB pathway inhibitor and, thus, to be involved in the activation of NF-κB signaling. Therefore, an NF-κB/miR-18a/NF-κB positive feedback loop might exist in NPC cells. Moreover, we showed that miR-18a expression was increased in LMP1-transfected NPC cell lines, and decreased in LMP1-knockdown C666-1 cells, suggesting that LMP1 might increase miR-18a expression in NPC cells. LMP1 mimics a constitutively activated tumor necrosis factor receptor, and induces transformation and promotes tumor progression by activating the NF-κB transcription factor pathway, the MAP kinase cascade, and the PI3K/AKT pathway in NPC cells. Recent studies have shown that LMP1 regulates the aberrant expression of certain cellular miRNAs involved in tumorigenesis, including miR-146a and miR-155 in EBV-related B-cell malignancies, miR-200 in EBV associated gastric carcinoma, and miR-203 in NPC. Our findings suggested that LMP1 might induce miR-18a expression through the NF-κB pathway. Since LMP1 has been reported to activate mTOR pathway in NPC cells, which is confirmed in this study (Fig. 6c), it raises a possibility that LMP1-induced mTOR activation might be mediated by miR-18a. However, the previous study showed that LMP1 activated mTOR signaling pathway through its upstream mediator PI3K/AKT in NPC. Therefore, multiple signaling pathways might be involved in the regulation of mTOR by LMP1. Further experiments were needed to clarify the significance of miR-18a in the role of LMP1.

As shown in Table 1, no significant relation was found between miR-18a expression and EBV serological biomarkers of the NPC patients, which is not consistent with our finding that LMP1 upregulates miR-18a. It might be explained as follows: Firstly, EBV latent products were consistently detected in NPC tumors even in serological negative patients since and EBV DNA was known to reside in all the tumor cells of NPC. Secondly, almost all NPC tumors exhibit aberrant NF-κB activation, which can be triggered by pro-inflammatory stimuli or genetic mutations of upstream components in addition to LMP1 expression. Lastly, previous studies showed that miR-18a can also be regulated by c-Myc, Notch signaling and E2F Transcription Factors. Therefore, miR-18a expression might be upregulated through pathways in addition to LMP1-induced NF-κB activation.

Our in vivo study demonstrated that ectopic miR-18a could effectively enhance tumor growth in the pretreated mice xenograft models. More importantly, the therapeutic mice xenograft model demonstrated that synthetic antagonir-18a, which can efficiently and stably knockdown miR-18a specifically in living cells, could strongly block the tumor growth after the second intratumoral injection without significant toxicity. miRNA targeting therapy has attracted more and more attention and successfully used in multiple human diseases. Although NPC is radiosensitive, the prognosis for NPC is still poor even with the use of neoadjuvant therapy. Therefore, the development of new therapeutic approaches is warranted. Our study indicates that antagonir-18a may ultimately be clinically useful in the treatment of NPC.

In conclusion, our results suggest a novel oncogenic miR-18a/SMG1/mTOR axis and provide a rationale for investigation of miR-18a as a novel therapeutic target in NPC.
1. Zhang, L. et al. Incidence trend of nasopharyngeal carcinoma from 1987 to 2011 in Shui County, Guangdong Province, South China: an age-period-cohort analysis. Chin. J. Cancer 34, 350–357 (2015).

2. Kuang-Rong, W. et al. Nasopharyngeal carcinoma incidence and mortality in China. Chin. J. Cancer 36, 686–693 (2017).

3. Xu, F. et al. An epidemiological and molecular study of the relationship between smoking, risk of nasopharyngeal carcinoma, and Epstein-Barr virus activation. J. Natl. Cancer Inst. 104, 1396–1410 (2012).

4. Ho, F. C., Tham, J. W., Earnest, A., Lee, K. M. & Lu, J. J. Patterns of regional lymph node metastasis of nasopharyngeal carcinoma: a meta-analysis of clinical evidence. BMC Cancer 12, 98–98 (2012).

5. Tso, C. et al. Prognostic scoring system for locoregional control among the patients with nasopharyngeal carcinoma treated by intensity-modulated radiotherapy. Chin. J. Cancer 32, 494–501 (2013).

6. Colaco, R. J. et al. Nasopharyngeal carcinoma – a retrospective review of demographics, treatment and patient outcome in a single centre. Clin. Oncol. 25, 171–177 (2013).

7. Ma, F., Wang, Z., Wang, J., Liu, X. & Hu, C. MicroRNA-19a promotes nasopharyngeal carcinoma by targeting transforming growth factor β receptor 2. Exp. Therap. Med. 14, 1419–1426 (2017).

8. Bahat, F., Emadi-Baygi, M. & Nikpour, P. miR-17-92 host gene, underexpressed in nasopharyngeal carcinoma, promotes proliferation and metastasis of nasopharyngeal carcinoma. Exp. Med. Oncol. 12, 3770–3780 (2013).

9. Wang, W. et al. Activation of Akt/mTOR pathway is associated with poor prognosis of nasopharyngeal carcinoma. PLoS ONE 9, e106098 (2014).

10. Yuan, J. et al. miR17HG-miR18a/19a axis, regulated by interferon regulatory factor-1, promotes gastric cancer metastasis via Wnt/beta-catenin signalling. Cell Death Dis. 10, 454 (2019).

11. Yi, M. et al. Rediscovery of NF-kappaB signaling in nasopharyngeal carcinoma: how genetic defects of NF-kappaB pathway interplay with EBV in driving oncogenesis? J. Cell Physiol. 233, 5537–5549 (2018).

12. Jeon, Y. J. et al. A set of NF-kappaB-regulated microRNAs induces acquired TRAIL resistance in lung cancer. Proc. Natl. Acad. Sci. USA 112, E3355–E3364 (2015).

13. Lu, J. et al. Transcriptional activation of microRNA-34a by NF-kappa B in human esophageal cancer cells. BMC Mol. Biol. 13, 4–4 (2012).

14. Shin, V. Y. et al. NF-kB target miR-16 and miR-21 in gastric cancer involvement of prostaeglandin E receptors. Carcinogenesis 32, 240–245 (2011).

15. Trenkmann, M. et al. Tumor necrosis factor alpha-induced microRNA-18a activates rheumatoid arthritis synovial fibroblasts through a feedback loop in NF-kappaB signaling. Arthritis Rheum. 65, 916–927 (2013).

16. Nakano, Y. et al. Progression of understanding for the role of Epstein-Barr virus and management of nasopharyngeal carcinoma. Cancer Metastasis Rev. 36, 433–447 (2017).

17. Dawson, C. W., Tramontanis, G., Ellipoulous, A. G. & Young, L. S. Epstein-Barr virus latent membrane protein 1 (LMP1) activates the phosphatidylinositol 3-kinase/Akt pathway to promote cell survival and induce actin filament remodeling. J. Biol. Chem. 278, 3694–3704 (2003).

18. Wang, L. W., Jiang, S. & Gewurz, B. E. Epstein-Barr virus LMP1-mediated oncogenicity. J. Virol. 91, e01718–16 (2017).

19. Cameron, J. E. et al. Epstein-Barr virus latent membrane protein 1 induces cellular microRNA miR-146a, a modulator of lymphocyte signaling pathways. J. Virol. 82, 1946–1958 (2008).

20. Gatto, G. et al. Epstein-Barr virus latent membrane protein 1 trans-activates miR-155 transcription through the NF-kappaB pathway. Nucleic Acids Res. 36, 6608 (2008).

21. Shinozaki, A. et al. Downregulation of microRNA-200 in EBV-associated gastric carcinoma. Cancer Res. 70, 4719–4727 (2010).

22. Hu, Y. et al. Epstein-Barr virus downregulates microRNA-203 through the oncprotein latent membrane protein. J. Virol. 86, 3088–3099 (2012).

23. Chen, J. et al. Epstein-Barr virus encoded latent membrane protein 1 regulates miTOR signaling pathway genes which predict poor prognosis of nasopharyngeal carcinoma. J. Transl. Med. 8, 30 (2010).

24. Shi, W. et al. Multiple dysregulated pathways in nasopharyngeal carcinoma revealed by gene expression profiling. Int. J. Cancer 119, 2467–2475 (2006).

25. Fuziwara, C. S. & Kimura, E. T. Insights into Regulation of the miR-17-92 Cluster of miRNAs in Cancer. Front. Med. 2, 64 (2015).

26. Woods, K., Thomson, J. M. & Hammond, S. M. Direct regulation of an oncogenic microRNA cluster by EZF transcription factors. J. Biol. Chem. 282, 2130–2134 (2007).